SCHEMBL734727

SCHEMBL734727

COC(=O)C(CCO)N1CCN(c2cccc(C(F)(F)F)c2)C(C)C1=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.42
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ALOX15 P16050 1/20 0.39
HTR7 P34969 1/20 0.39
NOTUM Q6P988 1/20 0.39
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
MGLL Q99685 2/20 0.38
ACACB O00763 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM3 P20309 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734643 0.88 HSD17B10 (0.44) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL733975 0.88 NOTUM (0.41) NOTUMACACBCHRM2CHRM4
SCHEMBL735209 0.85 POLB (0.44) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL734902 0.83 HSD17B10 (0.38) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL733679 0.83 HSD17B10 (0.38) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL733678 0.83 HSD17B10 (0.38) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL735608 0.80 POLB (0.53) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL735607 0.80 POLB (0.53) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL736396 0.80 POLB (0.53) HSD17B10LMNASMN1; SMN2POLBALDH1A1
SCHEMBL27933836 0.79 NOTUM (0.45) NOTUMACACBCHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 HSD17B10 3092/4885LMNA 3760/4885SMN1; SMN2 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.